Sponsor:
UI Contact:
Updated Date:
The National Institutes of Health, through its NIH Guide, has recently published the following funding-related notices and funding opportunities:
General Notices
- Notice of Information: National Institute of Biomedical Imaging and Bioengineering (NIBIB) to Issue Single Source Award to Support NeuroImaging Tools and Resources Collaboratory (NITRC)
(NOT-EB-23-011)
National Institute of Biomedical Imaging and Bioengineering
- Notice of Pre-Application Webinar for RFA-ES-23-007 "Exploratory Grants for Climate Change and Health Research Center Development (P20 Clinical Trial Optional)"
(NOT-ES-23-014)
National Institute of Environmental Health Sciences
- Notice of a Question and Answer "Office Hour" with NIGMS Staff for Bridges to the Baccalaureate and Bridges to the Doctorate Applicants
(NOT-GM-23-050)
National Institute of General Medical Sciences
- Notice of Technical Assistance Webinar for RFA-MH-24-150, "Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical High Risk for Psychosis Clinical Trial Network (U01 Clinical Trial Required)"
(NOT-MH-23-365)
National Institute of Mental Health
- Request for Information (RFI) on Opportunities for Biomarker Research in Amyotrophic Lateral Sclerosis (ALS)
(NOT-NS-23-097)
National Institute of Neurological Disorders and Stroke
Notice of Changes to Funding Opportunities
- Notice of Change to Eligibility Requirements for Program Directors/Principal Investigators in PAR-22-227, NIA Research and Entrepreneurial Development Immersion (REDI): Mentored Entrepreneurial Career Development Award (K01 Clinical Trial Not Allowed)
(NOT-AG-23-042)
National Institute on Aging
- Notice of Need to Expire and Reissue NOT-AT-21-013 "Notice of Special Interest: National Center for Complementary and Integrative Health (NCCIH) T32 Supplement Program for Pre and Postdoctoral Candidates from Diverse Backgrounds" to Change the Due Dates
(NOT-AT-24-011)
National Center for Complementary and Integrative Health
- Notice to Extend the Response date for NOT-DC-23-013, "Request for Information (RFI): Inviting Input Regarding NIDCDs Research Directions to Support Communication in Minimally Verbal/Non-Speaking People"
(NOT-DC-23-014)
National Institute on Deafness and Other Communication Disorders
- Notice of Change to Key Dates for PAR-23-029, NCMRR Early Career Research Award (R03 Clinical Trial Optional)
(NOT-HD-23-019)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Notice NICHD Participation on PAR-23-190: "Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, treatment and Care in Low- and Middle-Income Countries (R01 - Clinical Trial Optional)
(NOT-HD-23-020)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Notice of Correction to Eligibility Criteria for RFA-HL-23-007 Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARRTS) (K38 Clinical Trial Not Allowed)
(NOT-HL-23-100)
National Heart, Lung, and Blood Institute
- Notice of Change: Extension of PAR-20-285 "NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)"
(NOT-NS-23-094)
National Institute of Neurological Disorders and Stroke
Notices of Intent to Publish
- Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Limited Competition: Clinical Centers for Completion of the Outcomes of Babies with Opioid Exposure (OBOE) Study (UG1 Clinical Trial Not Allowed)
(NOT-HD-23-022)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Limited Competition: Data Coordinating Center for Completion of the Outcomes of Babies with Opioid Exposure (OBOE) Study (U24 Clinical Trial Not Allowed)
(NOT-HD-23-023)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Notice of Intent to Publish a Funding Opportunity Announcement for Diagnostic Centers of Excellence (U01 - Clinical Trial Not Allowed)
(NOT-NS-23-096)
National Institute of Neurological Disorders and Stroke
Notices of Special Interest
- Notice of Special Interest (NOSI): Administrative Supplement for Collaborative Projects Supported by the NIAID/RNCP
(NOT-AI-23-044)
National Institute of Allergy and Infectious Diseases
- Notice of Special Interest (NOSI): Administrative Supplements to support research by Diversity, Equity, Inclusion, and Accessibility (DEIA) Mentors at NIMHD-Funded Research Centers in Minority Institutions (RCMI)
(NOT-MD-23-016)
National Institute on Minority Health and Health Disparities
Office of the Director, NIH
- Notice of Special Interest (NOSI): Innovative Technologies to develop novel tools to prevent and treat HIV in underserved populations
(NOT-MH-23-200)
National Institute of Mental Health
Funding Opportunities
- Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)
(PAR-23-238)
National Institute of Mental Health
- Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)
(PAR-23-239)
National Institute of Mental Health
- Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
(PAR-23-246)
National Cancer Institute
- Health Equity and the Cost of Novel Treatments for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed)
(RFA-AG-24-050)
National Institute on Aging
- NIH-DoD-VA Pain Management Collaboratory ? Pragmatic and/or Implementation Science Demonstration Projects ((UG3/UH3) Clinical Trial Required)
(RFA-AT-24-004)
National Center for Complementary and Integrative Health
National Institute of Nursing Research
Office of Behavioral and Social Sciences Research
Office of Disease Prevention
- Mechanisms of Fusion-Driven Oncogenesis in Childhood Cancers (U01 Clinical Trial Not Allowed)
(RFA-CA-23-036)
National Cancer Institute
- Next Generation Chemistry Centers for Fusion Oncoproteins (UM1 Clinical Trial Not Allowed)
(RFA-CA-23-037)
National Cancer Institute
- HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed)
(RFA-DA-24-063)
National Institute on Drug Abuse
National Center for Complementary and Integrative Health
National Institute on Aging
National Institute of Allergy and Infectious Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)
(RFA-DA-24-064)
National Institute on Drug Abuse
National Center for Complementary and Integrative Health
National Institute on Aging
National Institute of Allergy and Infectious Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
(RFA-DA-25-014)
National Institute on Drug Abuse
- Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial required)
(RFA-DA-25-019)
National Institute on Drug Abuse
Application Receipt Date(s): March 19, 2025 - Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional)
(RFA-DA-25-020)
National Institute on Drug Abuse
- The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R01 Clinical Trial Optional)
(RFA-HL-24-008)
National Heart, Lung, and Blood Institute
- The Role of Sleep Deficiency in Persons with Type 1 Diabetes: Sleep, Glycemic Control, and Cardiovascular Risk (R34 Clinical Trial Optional)
(RFA-HL-24-009)
National Heart, Lung, and Blood Institute
Members of the University of Iowa community may direct questions to the UI Division of Sponsored Programs at dsp@uiowa.edu(link sends e-mail)(link sends e-mail) or 313-335-2123, or email Ann Ricketts at ann-ricketts@uiowa.edu(link sends e-mail)(link sends e-mail) or Lynn Hudachek at lynn-hudachek@uiowa.edu(link sends e-mail)(link sends e-mail).